Foxo Technologies INC

FOXO Technologies' subsidiary, Vector BioSource, Inc., has entered into a definitive agreement to acquire four U.S.-based blood collection centers from Grifols Bio Supplies, Inc., aiming to enhance its bio-product sourcing and expand its market reach.

FOXO Technologies Inc. announced its subsidiary, Vector BioSource, Inc., has entered into an asset purchase agreement to acquire four U.S.-based blood collection centers from Grifols Bio Supplies, Inc.

FOXO Technologies Inc. CEO Seamus Lagan provided a mid-year update highlighting operational improvements, corporate restructuring, and strategic growth initiatives including potential acquisitions and a stock exchange uplisting.

FOXO Technologies Inc. announced the effectiveness of its 1-for-3,000 reverse stock split, aimed at increasing its per-share stock price for potential OTCQB quotation and future exchange uplisting.

FOXO Technologies has entered into an exclusive licensing agreement with founder Jon R. Sabes to commercialize its epigenetics intellectual property portfolio.

FOXO Technologies has reached a settlement with J.H. Darbie & Co. and received majority shareholder approval for a massive reverse stock split.

FOXO Technologies Inc. reported a net loss of $1.5 million for the first quarter of 2026, with revenues increasing by 63% to $5.2 million.

FOXO Technologies reported a significant revenue increase in Q3 2025 driven by recent acquisitions, but faces ongoing delisting from NYSE American, substantial losses to common stockholders, and a going concern doubt.

FOXO Technologies Inc. reported a significant revenue increase in Q2 2025 driven by recent healthcare acquisitions, but faces substantial doubt about its going concern ability and delisting from NYSE American.

FOXO Technologies Inc. has restated its first-quarter 2025 financial statements due to an accounting error related to a recent acquisition, revealing a significantly increased working capital deficit and continued substantial doubt about its ability to continue as a going concern.

FOXO Technologies' Q1 2025 results show a shift towards healthcare with significant revenue from recent acquisitions, alongside ongoing efforts to manage debt and improve financial stability.

FOXO Technologies' third quarter 2024 results reflect the impact of recent acquisitions in the healthcare sector, alongside ongoing developments in its Labs and Life segment.

FOXO Technologies Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2025, detailing significant revenue growth driven by recent acquisitions, alongside ongoing efforts to manage its financial position and capital structure.

FOXO Technologies amends its termination agreement with KR8 AI to clarify the scope of the termination, focusing on financial obligations rather than the entire agreement.

FOXO Technologies Inc. is exploring strategic alternatives, including a potential merger, while focusing on its Bioinformatics Services and AI-driven health solutions due to financial constraints.

Kr8 ai Inc., a 10% owner of FOXO TECHNOLOGIES INC., disposed of 1,300,000 shares of Class A Common Stock at a price of $0.25 per share on July 22, 2024.

Interim CEO Mark Brian White reports the sale of 1,300,000 shares of FOXO Technologies Inc. at $0.25 per share through KR8 ai Inc.

Interim CFO Martin Ward reports the sale of 1,300,000 shares of FOXO Technologies Inc. through KR8 ai Inc.

FOXO Technologies Inc. announces an increase in authorized common and preferred stock, re-election of its board, and ratification of its auditor, all approved by majority shareholder consent.

FOXO Technologies Inc. has increased its authorized Class A Common Stock to 2.5 billion shares to meet existing financing obligations and enable future capital raising.

FOXO Technologies intends to execute a reverse stock split to boost its stock price and attract institutional investors.

A majority shareholder has approved multiple equity issuances and a reverse stock split to ensure compliance with NYSE American listing requirements and facilitate ongoing capital raising efforts.

FOXO Technologies Inc. has informed stockholders of approvals for substantial share issuances to ClearThink Capital Partners, LLC, Jefferson Street Capital, LLC, and other investors from convertible notes and promissory note exchanges, alongside a recent 1-for-10 reverse stock split, all aimed at maintaining NYSE American listing compliance.

FOXO Technologies is holding a special meeting to seek shareholder approval for the conversion of Series A Preferred Stock into common stock and related voting terms, which could result in a change of control.

FOXO Technologies Inc. has filed an S-1 registration statement to allow selling stockholders to resell up to 10 million shares of Class A Common Stock, while the company faces a going concern warning and continues its strategic shift into healthcare services.

FOXO Technologies is registering the resale of up to 4 million shares of Class A Common Stock by selling stockholders, as the company grapples with funding its operations beyond December 2025.

Sabby Management, Hal Mintz, and Sabby Volatility Warrant Master Fund have reported a combined 9.9% beneficial ownership in FOXO Technologies Inc. common stock.